Back to top
more

Gilead Sciences (GILD)

(Delayed Data from NSDQ)

$83.61 USD

83.61
5,456,718

+0.57 (0.69%)

Updated Sep 27, 2024 04:00 PM ET

After-Market: $83.61 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value B Growth A Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 35% (89 out of 251)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

The Zacks Analyst Blog Highlights: Gilead Sciences, Pfizer, Sanofi, GlaxoSmithKline and Moderna

by Zacks Equity Research

The Zacks Analyst Blog Highlights: Gilead Sciences, Pfizer, Sanofi, GlaxoSmithKline and Moderna

The Zacks Analyst Blog Highlights: Amazon, Apple, Gilead Sciences, Amgen and Visa

by Zacks Equity Research

The Zacks Analyst Blog Highlights: Amazon, Apple, Gilead Sciences, Amgen and Visa

Sanghamitra Saha headshot

ETF Asset Report of Coronavirus-Inflicted April

by Sanghamitra Saha

These ETF areas have gained or lost assets in the month of April.

Sanghamitra Saha headshot

5 Top-Performing ETF Areas of April That Are Up At Least 25%

by Sanghamitra Saha

These ETF areas showered gains in the lockdown-infected April.

Mark Vickery headshot

Amazon Misses on Earnings, Apple Beats but Trades Lower

by Mark Vickery

Amazon came in well below earnings estimates, Apple beats on both top & bottom, plus results from Gilead, Amgen and Visa.

Gilead Sciences (GILD) Q1 Earnings and Revenues Beat Estimates

by Zacks Equity Research

Gilead (GILD) delivered earnings and revenue surprises of 6.33% and 2.61%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

Sweta Jaiswal, FRM headshot

Biotech ETFs Gain on New Positive Data for Gilead's Remdesivir

by Sweta Jaiswal, FRM

As the coronavirus continues to spread, the latest positive data on remdesivir is some relief in such challenging times.

The Zacks Analyst Blog Highlights: Cisco, Abbott Laboratories, NextEra Energy, Gilead Sciences and Edwards Lifesciences

by Zacks Equity Research

The Zacks Analyst Blog Highlights: Cisco, Abbott Laboratories, NextEra Energy, Gilead Sciences and Edwards Lifesciences

Stock Market News for Apr 30, 2020

by Zacks Equity Research

U.S. stocks closed sharply higher on Wednesday following positive clinical trial data of a drug for potential coronavirus treatment.

Ritujay Ghosh headshot

Remdesivir Progresses on Coronavirus Trial: Pharma Upbeat

by Ritujay Ghosh

A large number of biotech companies have been working on developing drugs and vaccine for the novel coronavirus that has infected more than 3,100,000 and claimed 227,000 lives.

Sanghamitra Saha headshot

5 Small-Cap ETFs Beating S&P 500 in April

by Sanghamitra Saha

Extension of the paycheck protection program, some forgivable loans, strong dollar and the talks of reopening of the economy supported the small-cap ETFs in April.

Sanghamitra Saha headshot

Leveraged Small-Cap and Inverse Leveraged Gold Miners: 2 ETFs to Watch on Outsized Volume

by Sanghamitra Saha

URTY and JDST have seen elevated trading volume on Wednesday.

Should You Buy Gilead Sciences (GILD) Ahead of Earnings?

by Zacks Equity Research

Gilead Sciences (GILD) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Gilead's Coronavirus Drug Shows Positive Data

by Zacks Equity Research

Gilead's Coronavirus Drug Shows Positive Data

Mark Vickery headshot

Positive Data for Gilead's (GILD) Remdesivir; Plus Q1 for BA, GE

by Mark Vickery

This is obviously remarkably good news for COVID-19 suffers, the general public in the throes of this pandemic, and of course Gilead itself.

Biotech Stocks Earnings Roster for Apr 30: AMGN, GILD & More

by Zacks Equity Research

Let us take a look at what is in store for some of the biotech stocks, which are scheduled to report on Apr 30.

Sheraz Mian headshot

Top Stock Research Reports for Cisco, Abbott, NextEra & Others

by Sheraz Mian

Today's Research Daily features new research reports on 16 major stocks, including Cisco (CSCO), Abbott Laboratories (ABT) and NextEra Energy (NEE).

Amgen (AMGN) to Report Q1 Earnings: What's in the Cards?

by Zacks Equity Research

Investor focus is likely to be on the impact of the coronavirus outbreak on Amgen's (AMGN) performance when it reports first-quarter results.

Sweta Killa headshot

First-Mover Pandemic Disease Fight ETF On The Way

by Sweta Killa

Pacer Financial has filed for Pacer BioThreat ETF to enjoy the first-mover advantage that provide investors an option to capitalize on the new opportunities triggered by coronavirus.

Will Strong HIV Sales Drive Gilead's (GILD) Q1 Earnings?

by Zacks Equity Research

Investors will focus on the HIV franchise's performance and the uptake of Yescarta along with updates on the experimental coronavirus treatment when Gilead (GILD) reports first-quarter 2020 results.

Should Franklin LibertyQ U.S. Equity ETF (FLQL) Be on Your Investing Radar?

by Zacks Equity Research

Style Box ETF report for FLQL

Focus on Coronavirus Treatments to Boost Biotech Stocks

by Zacks Equity Research

With the coronavirus pandemic raging on, biotech companies are in focus as they are racing against time to evaluate every possible therapy to combat the spread.

David Borun headshot

Equities See Modest Declines as Many Businesses Prepare to Reopen

by David Borun

A reduction in Coronavirus cases and public outcry have many states planning a resumption of business activities.

Sweta Jaiswal, FRM headshot

Ride Out the Coronavirus Mayhem With These ETF Areas

by Sweta Jaiswal, FRM

We discuss some ETF areas that investors can choose to invest for a smoother sail during the coronavirus pandemic.

Sweta Jaiswal, FRM headshot

Ride Out the Coronavirus Mayhem With These ETF Areas

by Sweta Jaiswal, FRM

We discuss some ETF areas that investors can choose to invest for a smoother sail during the coronavirus pandemic.